KLTO (Klotho Neurosciences) Buyback Yield %: 0.00 (As of Jul. 02, 2026)


KLTO Klotho Neurosciences Inc KLTO
22 GF Score
Price $0.52
! 1 Warning Sign
View Full Analysis

What is Klotho Neurosciences Buyback Yield %?

Klotho Neurosciences KLTO 22 Buyback Yield % is 0.00 as of Jul. 02, 2026. GuruFocus rates KLTO with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Klotho Neurosciences's current buyback yield was 0.00%.

Klotho Neurosciences Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Klotho Neurosciences's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klotho Neurosciences Buyback Yield % Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Buyback Yield %
0.00 0.00 0.00 -1.33

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.33 0.00 0.00 0.00

KLTO vs KTTA, JUNS, ZEOX: Buyback Yield % Comparison

For the Biotechnology subindustry, Klotho Neurosciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Klotho Neurosciences Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Buyback Yield % falls into.


KLTO
22GF Score
Klotho Neurosciences Inc KLTO
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Klotho Neurosciences Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Klotho Neurosciences's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.12 + 0.295) / 13.134285
=-1.33%

Klotho Neurosciences's annualized Buyback Yield for the quarter that ended in Sep. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 34.084341
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Klotho Neurosciences (KLTO) has a Buyback Yield % of 0.00 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Klotho Neurosciences and its competitors.
Is Klotho Neurosciences' Buyback Yield % too high?
Klotho Neurosciences' current Buyback Yield % is 0.00. Overall, Klotho Neurosciences has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Klotho Neurosciences' Buyback Yield % compare to KTTA and JUNS?
Klotho Neurosciences' Buyback Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Klotho Neurosciences and its competitors. Klotho Neurosciences's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klotho Neurosciences stock overvalued right now?
Klotho Neurosciences (KLTO) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Klotho Neurosciences' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Klotho Neurosciences (KLTO), the current Buyback Yield % is 0.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Klotho Neurosciences Business Description

Address 13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
22GF Score

Get the complete analysis for KLTO

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price